ZnO is pH sensitive and allows for controlled release of Zn2+ and loaded drugs in the tumor microenvironment. EGFR antibody or EGFR KTI provides specific targeting and inhibition. Nanotheranostic platforms can realize synergistic therapy. The gene discussed is EGFR; the disease is neoplasm.